α-synuclein genetic variability: A biomarker for dementia in Parkinson disease

α-synuclein genetic variability: A biomarker for dementia in Parkinson disease

Objective<br/> The relationship between Parkinson disease (PD), PD with dementia (PDD), and dementia with Lewy bodies (DLB) has long been debated. Although PD is primarily considered a motor disorder, cognitive impairment is often present at diagnosis, and only ∼20% of patients remain cognitiv...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Guella, I, Evans, D, Szu-Tu, C, Nosova, E, Bortnick, S, Goldman, J, Dalrymple-Alford, J, Geurtsen, G, Litvan, I, Ross, O, Middleton, L, Parkkinen, L, Farrer, M
Format:	Journal article
Veröffentlicht:	Wiley 2016

Ähnliche Einträge

Mild cognitive impairment as a risk factor for Parkinson's disease dementia
von: Hoogland, J, et al.
Veröffentlicht: (2017)

Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia
von: Parkkinen, L, et al.
Veröffentlicht: (2004)

The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia
von: Compta, Y, et al.
Veröffentlicht: (2013)

Risk of Parkinson's disease dementia related to level I MDS PD-MCI
von: Hoogland, J, et al.
Veröffentlicht: (2019)

A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism
von: Adam Book, et al.
Veröffentlicht: (2018-12-01)

Relationship of Apolipoprotein E to Parkinson's disease-related alpha-synuclein pathology
von: Parkkinen, L, et al.
Veröffentlicht: (2013)

Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis
von: Simone A. van den Berge, et al.
Veröffentlicht: (2012-01-01)

Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance
von: Parkkinen, L, et al.
Veröffentlicht: (2008)

Colonic mucosal -synuclein lacks specificity as a biomarker for Parkinson disease
von: Ruffmann, C, et al.
Veröffentlicht: (2015)

Widespread and abundant α-synuclein pathology in a neurologically unimpaired subject
von: Parkkinen, L, et al.
Veröffentlicht: (2005)

Mitochondria-targeted oligomeric α-synuclein induces TOM40 degradation and mitochondrial dysfunction in Parkinson’s disease and parkinsonism-dementia of Guam
von: Velmarini Vasquez, et al.
Veröffentlicht: (2024-12-01)

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.
von: Zarranz, J, et al.
Veröffentlicht: (2004)

Gut feelings about α-synuclein in gastrointestinal biopsies: biomarker in the making?
von: Ruffmann, C, et al.
Veröffentlicht: (2016)

α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease
von: Cecilia S. Lindestam Arlehamn, et al.
Veröffentlicht: (2020-04-01)

Colonic Alpha-Synuclein as Potential Early Biomarker for Parkinson's Disease Dementia
von: Elvan Wiyarta
Veröffentlicht: (2022-06-01)

Differential Circulating Levels of Naturally Occurring Antibody to α-Synuclein in Parkinson’s Disease Dementia, Alzheimer’s Disease, and Vascular Dementia
von: Jian Wang, et al.
Veröffentlicht: (2020-09-01)

α-Synuclein and dopamine at the crossroads of Parkinson's disease.
von: Venda, L, et al.
Veröffentlicht: (2010)

Detection of alpha-synuclein conformational variants from gastro-intestinal biopsy tissue as a potential biomarker for Parkinson's disease
von: Ruffmann, C, et al.
Veröffentlicht: (2018)

Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease
von: Parkkinen, L, et al.
Veröffentlicht: (2003)

Accumulation of Insoluble α-Synuclein in Dementia with Lewy Bodies
von: Bruce C.V. Campbell, et al.
Veröffentlicht: (2000-06-01)

Abundant glial alpha-synuclein pathology in a case without overt clinical symptoms
von: Parkkinen, L, et al.
Veröffentlicht: (2007)

Parkinson’s Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron
von: Jiajun Han, et al.
Veröffentlicht: (2021-10-01)

Assessment of α-Synuclein Pathology
von: Alafuzoff, I, et al.
Veröffentlicht: (2008)

Gut feeling about alpha-synuclein in gastro-intestinal biopsies: biomarker in the making?
von: Ruffmann, C, et al.
Veröffentlicht: (2015)

Biomarkers and the Role of α-Synuclein in Parkinson’s Disease
von: Tingting Du, et al.
Veröffentlicht: (2021-03-01)

Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
von: Victorio M. Pozo Devoto, et al.
Veröffentlicht: (2017-09-01)

Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease
von: Derya Emin, et al.
Veröffentlicht: (2022-09-01)

α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls.
von: Lynnae M Smith, et al.
Veröffentlicht: (2012-01-01)

Initiation and progression of α-synuclein pathology in Parkinson’s disease
von: Tofaris, GK
Veröffentlicht: (2022)

ODE/PDE α-synuclein Models for Parkinson’s Disease /
von: Schiesser, William E., author 194177, et al.
Veröffentlicht: (2018)

The Contribution of α-Synuclein Spreading to Parkinson’s Disease Synaptopathy
von: Francesca Longhena, et al.
Veröffentlicht: (2017-01-01)

Navigating the Neurobiology of Parkinson’s: The Impact and Potential of α-Synuclein
von: Erlandas Paulėkas, et al.
Veröffentlicht: (2024-09-01)

The Convergence of Dopamine and α-Synuclein: Implications for Parkinson’s Disease
von: Danielle E Mor, et al.
Veröffentlicht: (2018-03-01)

Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease
von: Jessika C. Bridi, et al.
Veröffentlicht: (2018-02-01)

“Janus-Faced” α-Synuclein: Role in Parkinson’s Disease
von: Bipul Ray, et al.
Veröffentlicht: (2021-05-01)

Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies
von: Connor Bargar, et al.
Veröffentlicht: (2021-04-01)

Postmortem Interval Influences α-Synuclein Expression in Parkinson Disease Brain
von: Alexandra Dumitriu, et al.
Veröffentlicht: (2012-01-01)

Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson’s disease and dementia with Lewy bodies
von: Irene Frigerio, et al.
Veröffentlicht: (2024-01-01)

DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study
von: Parkkinen, L, et al.
Veröffentlicht: (2016)

Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia
von: Rebecca L. Miller, et al.
Veröffentlicht: (2022-02-01)